SCHEMBL16075019

SCHEMBL16075019

C=CC(=O)N1CCC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 1.00
EGFR P00533 4/20 0.77
TEC P42680 3/20 0.72
BMX P51813 3/20 0.72
TXK P42681 2/20 0.72
LYN P07948 2/20 0.72
FGFR2 P21802 2/20 0.72
ITK Q08881 2/20 0.72
RIPK2 O43353 1/20 0.72
NR1I2 O75469 1/20 0.72
SLC22A3 O75751 1/20 0.72
LATS1 O95835 1/20 0.72
NUDT14 O95848 1/20 0.72
ABL1 P00519 1/20 0.72
ERBB2 P04626 1/20 0.72
LCK P06239 1/20 0.72
FYN P06241 1/20 0.72
PGR P06401 1/20 0.72
CSF1R P07333 1/20 0.72
YES1 P07947 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15155454 0.96 BTK (0.92) BTKEGFRTECBMXTXK
SCHEMBL15155363 0.95 BTK (0.91) BTKEGFRTECBMXTXK
SCHEMBL15155117 0.94 BTK (1.00) BTKEGFRTECBMXTXK
SCHEMBL15155348 0.90 BTK (0.85) BTKEGFRTECBMXTXK
SCHEMBL15155291 0.88 BTK (0.79) BTKEGFRTECBMXTXK
SCHEMBL19176295 0.88 BTK (0.78) BTKEGFRTECBMXTXK
SCHEMBL15155121 0.87 BTK (0.77) BTKEGFRTECBMXTXK
SCHEMBL16075015 0.87 BTK (0.77) BTKEGFRLYNNUDT14LCK
SCHEMBL202187 0.87 BTK (1.00) BTKEGFRTECBMXTXK
SCHEMBL16375290 0.86 BTK (0.76) BTKEGFRTECBMXTXK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970300-B1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2018-05-16 EP disclosed
US-8940893-B2 Heteroaromatic compounds as BTK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-27 US disclosed
US-8940893-B2 Heteroaromatic compounds as BTK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-27 US disclosed
US-20140275014-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-18 US disclosed
US-20140275014-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275014-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BTK, SYK, LYN BTK 1/4885EGFR 239/4885TEC 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.